28.06.2016
amp biosimilars AG DE000A0SMU87
DGAP-News: amp biosimilars announces Klaus K. Wilgenbus as new CEO
DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel
amp biosimilars announces Klaus K. Wilgenbus as new CEO
28.06.2016 / 08:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
amp biosimilars announces Klaus K. Wilgenbus as new CEO
- Experienced industry executive to start as new CEO on July 1
- Founding CEO Marc W. Hentz steps down in a planned succession move
Hamburg, Germany, June 28 2016 - amp biosimilars AG (ISIN: DE000A0SMU87), a
company specializing in the development of high-quality biosimilars, today
announced that Klaus K. Wilgenbus will lead the firm as the new CEO from
July 1, 2016.
In 2014 Klaus Wilgenbus retired as Corp. Senior VP Business Development
Licensing and Strategy from Boehringer Ingelheim (BI). During his 18 year
tenure at BI he held various positions covering Business Development, R&D,
innovation management, corporate and commercial strategy, and
organizational development. Under his leadership BI has entered into more
than 200 strategic transactions incl. R&D collaborations, global
co-promotion and co-marketing alliances, JV's and merger and acquisitions
with business partners from North-America, EU and Asia. Klaus Wilgenbus
also served on various boards such as Karolinska Development AB (Solna
Sweden), Actimis Inc. (San Diego) and Boehringer Ingelheim Deutschland GmbH
& Co KG and represented BI at the Board of (US) BIO. After 2014 Klaus
Wilgenbus served as interim-CEO at Karolinska Development AB and advised as
independent consultant small to mid sized biotech companies and life
sciences investors in the areas of corporate strategy, fundraising and
business transactions. Wilgenbus was trained as a physician in Germany and
the US and holds an MD from RWTH Aachen.
"It's an exciting time to be joining amp biosimilars, with the company's
product and deal pipeline growing rapidly" said Wilgenbus. "I look forward
to joining the amp team in order to advance the development of new
high-quality therapies for patients in both the pharmerging and the
regulated markets, the primary focus of the work at amp."
Founding CEO Dr. Marc W. Hentz retires from the post in a planned
succession move. "I am excited that we can implement our plan to attract an
experienced industry leader to join amp for its next phase of corporate
development. The Board's appointment of Klaus Wilgenbus is a testimony to
our success and strategic direction, and I sincerely congratulate him.
Klaus is an experienced biopharma executive and an outstanding dealmaker
whose skill-set will directly contribute to the firm's future growth path.
As a founder and shareholder I am excited about his future impact on the
company and will continue to support amp in any advisory or other capacity
required."
Chairman of amp Supervisory Board Dr. Thomas Zimmer comments: "With Klaus
Wilgenbus we have identified a leading pharma executive who brings a
tremendous wealth of pharma and biotech knowhow to amp biosimilars AG. The
addition of his business acumen enhances our ability to deliver high-value
biosimilars for the future. I thank Marc Hentz for his 2 years of
successful leadership in building the company and securing its first out
licensing deals, and I am sure that Klaus Wilgenbus will ensure the
continued expansion of our position as leader in biosimilar development."
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com.
Contact:
Fabian Lorenz
Florenz Kommunikation
T: +49 211 29831588
E-mail: [email protected]
---------------------------------------------------------------------------
28.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: amp biosimilars AG
Am Kaiserkai 1
22391 Hamburg
Germany
Phone: +49 40 80 80 74 760
Internet: http://www.ampbiosimilars.com
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Munich
End of News DGAP News Service
---------------------------------------------------------------------------
474787 28.06.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
amp biosimilars AG ISIN: DE000A0SMU87 können Sie bei EQS abrufen
IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2